GenSci048 Phase 2 Uveitis Efficacy Safety Study
ClinicalTrials.gov Studies
Summary
NIH ClinicalTrials.gov has registered Phase 2 study NCT07547995, a randomized trial evaluating the efficacy and safety of GenSci048 versus placebo in subjects with active non-infectious uveitis. The study will assess two dose levels of GenSci048 against a placebo control group. This registry entry provides public transparency on the trial design, conditions, and interventions for the investigational drug being studied for ocular inflammation.
“This study is designed to evaluate the efficacy and safety of GenSci048 compared with placebo in subjects with active non-infectious uveitis.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
NIH ClinicalTrials.gov has registered a new Phase 2 clinical study, NCT07547995, titled 'A Study of Efficacy and Safety of GenSci048 in Subjects With Active Uveitis.' The trial will evaluate GenSci048 at two dose levels against placebo in patients with active non-infectious uveitis, an inflammatory eye condition. The study is categorized as Phase 2 and was posted on April 23, 2026.
Pharmaceutical companies and clinical investigators conducting trials for ocular inflammatory conditions should note this trial registration as part of the clinical development landscape for uveitis therapeutics. The registry entry provides structured information on the study design and intervention arms that may inform competitive intelligence or patient-referral considerations.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Study of Efficacy and Safety of GenSci048 in Subjects With Active Uveitis.
Phase 2 NCT07547995 Kind: PHASE2 Apr 23, 2026
Abstract
This study is designed to evaluate the efficacy and safety of GenSci048 compared with placebo in subjects with active non-infectious uveitis.
Conditions: Uveitis
Interventions: GenSci048 High-dose, GenSci048 Low-dose, Placebo
Mentioned entities
Parties
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.